arrow
T

Taro Yamashita

Kanazawa University
H指数:55
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Chromatin Accessibility-Guided Targeting Identifies Structurally Constrained Regions in HBV cccDNA and Suppresses Viral Replication

染色质可及性指导靶向识别HBV cccDNA中的结构限制区域并抑制病毒复制

2026-08-040
OA
Potential Role of Liver Transplantation for Child–Pugh Class A Hepatocellular Carcinoma: Prognosis and Medical Expenditure in Japan—A Retrospective Single-Center Study

对于Child–Pugh A级肝细胞癌的肝移植潜在作用:预后与医疗支出——一项回顾性单中心研究

2026-06-220
OAAI
Correction: Ishida et al. Wnt/β-Catenin Signaling Regulates Hepatitis B Virus cccDNA Levels. Int. J. Mol. Sci. 2025, 26, 6942

更正:Ishida等人 Wnt/β-连环蛋白信号通路调节乙型肝炎病毒共价闭合环状DNA水平。Int. J. Mol. Sci. 2025, 26, 6942

2026-05-300
OA
Real-World Evidence from a Nationwide Prospective Study of the Efficacy/Safety of Systemic Therapy for Unresectable Hepatocellular Carcinoma: First 1,000 Patients of the PRISM Study

全国性前瞻性研究中的真实世界证据:不可切除肝细胞癌系统性治疗的有效性/安全性分析——PRISM研究的前1000例患者

2026-05-010
PRE
Netrin-1 inhibits the attachment and internalization of Hepatitis B virus for hepatocyte infection

Netrin-1抑制乙型肝炎病毒对肝细胞的附着和内化感染

2025-12-170
PRE
Evaluation of Long-Read RNA Sequencing Procedures for Novel Isoform Identification and Quantification in Human Whole Blood

长读长RNA测序流程在人类全血中新型异构体鉴定与定量评估

2025-10-010
OAAI
Vascular Endothelial Growth Factor Receptor 2-Targeted Therapy Suppresses the Progression of Alpha-Fetoprotein-Positive Hepatocellular Carcinoma After Combination Therapy With Anti-Programmed Death-Ligand 1 and Anti-Vascular Endothelial Growth Factor-A Antibodies

血管内皮生长因子受体2靶向治疗抑制了联合程序性死亡配体1抗体和血管内皮生长因子A抗体治疗后,甲胎蛋白阳性肝细胞癌的进展。

2025-10-010
OAAI